All Metabolic dysfunction-associated steatotic liver disease (MASLD) articles
-
NewsPemafibrate and telmisartan combo may reverse fatty liver
A new study shows that approved drugs, pemafibrate and telmisartan, when combined, can reduce liver fat and may lower cardiovascular risk in metabolic dysfunction-associated steatotic liver disease.
-
NewsNew treatment for metabolic dysfunction-associated steatohepatitis
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.